CL2020001244A1 - Inhibidores de inmunoproteasoma. - Google Patents
Inhibidores de inmunoproteasoma.Info
- Publication number
- CL2020001244A1 CL2020001244A1 CL2020001244A CL2020001244A CL2020001244A1 CL 2020001244 A1 CL2020001244 A1 CL 2020001244A1 CL 2020001244 A CL2020001244 A CL 2020001244A CL 2020001244 A CL2020001244 A CL 2020001244A CL 2020001244 A1 CL2020001244 A1 CL 2020001244A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- description
- inhibitors
- immunoproteasome inhibitors
- immunoproteasome
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 abstract 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 abstract 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 abstract 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
EN LA PRESENTE DESCRIPCIÓN SE PROPORCIONAN COMPUESTOS, TALES COMO UN COMPUESTO DE LA FÓRMULA (I), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ESTE, QUE SON INHIBIDORES DE INMUNOPROTEASOMA (TALES COMO LMP2 Y LMP7). LOS COMPUESTOS DESCRITOS EN LA PRESENTE DESCRIPCIÓN PUEDEN SER ÚTILES PARA EL TRATAMIENTO DE ENFERMEDADES TRATABLES MEDIANTE LA INHIBICIÓN DE INMUNOPROTEASOMAS. EN LA PRESENTE DESCRIPCIÓN TAMBIÉN SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN TALES COMPUESTOS Y PROCESOS PARA PREPARAR TALES COMPUESTOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762587376P | 2017-11-16 | 2017-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020001244A1 true CL2020001244A1 (es) | 2020-08-21 |
Family
ID=64746633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020001244A CL2020001244A1 (es) | 2017-11-16 | 2020-05-12 | Inhibidores de inmunoproteasoma. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11225493B2 (es) |
| EP (1) | EP3710458A1 (es) |
| JP (1) | JP7277457B2 (es) |
| KR (1) | KR102625984B1 (es) |
| CN (1) | CN111491938B (es) |
| AU (1) | AU2018367515B2 (es) |
| CA (1) | CA3080949C (es) |
| CL (1) | CL2020001244A1 (es) |
| CO (1) | CO2020007150A2 (es) |
| EA (1) | EA202090900A1 (es) |
| IL (1) | IL274523B2 (es) |
| MA (1) | MA50906A (es) |
| MX (2) | MX2020005046A (es) |
| NZ (1) | NZ764393A (es) |
| PH (1) | PH12020550580A1 (es) |
| SG (1) | SG11202003867SA (es) |
| TW (1) | TWI837104B (es) |
| WO (1) | WO2019099582A1 (es) |
| ZA (1) | ZA202002531B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61811B1 (sr) * | 2017-01-18 | 2021-06-30 | Principia Biopharma Inc | Inhibitori imunoproteazoma |
| AU2018355743B2 (en) | 2017-10-27 | 2022-04-14 | Boehringer Ingelheim International Gmbh | Pyridine carbonyl derivatives and therapeutic uses thereof as TRPC6 inhibitors |
| HUE060020T2 (hu) | 2017-11-16 | 2023-01-28 | Principia Biopharma Inc | Immunproteaszóma-gátlók |
| CA3080949C (en) | 2017-11-16 | 2024-04-16 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| EP4417614A1 (en) | 2021-10-14 | 2024-08-21 | Shouyao Holdings (Beijing) Co., Ltd. | Boronic acid derivative |
| WO2024006337A1 (en) * | 2022-06-30 | 2024-01-04 | Principia Biopharma Inc. | Cyclic boronic esters and their uses |
| CN118255835A (zh) * | 2022-12-27 | 2024-06-28 | 上海美悦生物科技发展有限公司 | 三肽环氧酮化合物、药物组合物及其制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US4963655A (en) | 1988-05-27 | 1990-10-16 | Mayo Foundation For Medical Education And Research | Boron analogs of amino acid/peptide protease inhibitors |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| IL111175A0 (en) | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| US20050203027A1 (en) | 2004-02-23 | 2005-09-15 | Trustees Of Tufts College | Inhibitors of dipeptidylpeptidase IV |
| EP2542238B1 (en) * | 2010-03-01 | 2015-08-12 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| SG11201403254QA (en) | 2011-12-22 | 2014-07-30 | Ares Trading Sa | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
| EP3157909B1 (en) | 2014-06-20 | 2021-04-07 | Principia Biopharma Inc. | Lmp7 inhibitors |
| US10669289B2 (en) * | 2014-10-01 | 2020-06-02 | Merck Patent Gmbh | Boronic acid derivatives |
| CN106588965A (zh) * | 2015-10-15 | 2017-04-26 | 北京大学 | 脲拟肽硼酸化合物及其药物组合物、制备方法和用途 |
| RS61811B1 (sr) * | 2017-01-18 | 2021-06-30 | Principia Biopharma Inc | Inhibitori imunoproteazoma |
| CA3080949C (en) | 2017-11-16 | 2024-04-16 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| HUE060020T2 (hu) * | 2017-11-16 | 2023-01-28 | Principia Biopharma Inc | Immunproteaszóma-gátlók |
-
2018
- 2018-11-14 CA CA3080949A patent/CA3080949C/en active Active
- 2018-11-14 IL IL274523A patent/IL274523B2/en unknown
- 2018-11-14 EA EA202090900A patent/EA202090900A1/ru unknown
- 2018-11-14 JP JP2020527042A patent/JP7277457B2/ja active Active
- 2018-11-14 SG SG11202003867SA patent/SG11202003867SA/en unknown
- 2018-11-14 AU AU2018367515A patent/AU2018367515B2/en active Active
- 2018-11-14 KR KR1020207017251A patent/KR102625984B1/ko active IP Right Grant
- 2018-11-14 MA MA050906A patent/MA50906A/fr unknown
- 2018-11-14 EP EP18822543.7A patent/EP3710458A1/en active Pending
- 2018-11-14 CN CN201880074665.3A patent/CN111491938B/zh active Active
- 2018-11-14 NZ NZ764393A patent/NZ764393A/en unknown
- 2018-11-14 US US16/764,136 patent/US11225493B2/en active Active
- 2018-11-14 WO PCT/US2018/061140 patent/WO2019099582A1/en active Application Filing
- 2018-11-14 MX MX2020005046A patent/MX2020005046A/es unknown
- 2018-11-16 TW TW107140806A patent/TWI837104B/zh active
-
2020
- 2020-05-07 PH PH12020550580A patent/PH12020550580A1/en unknown
- 2020-05-07 ZA ZA2020/02531A patent/ZA202002531B/en unknown
- 2020-05-12 CL CL2020001244A patent/CL2020001244A1/es unknown
- 2020-06-11 CO CONC2020/0007150A patent/CO2020007150A2/es unknown
- 2020-07-13 MX MX2022012825A patent/MX2022012825A/es unknown
-
2021
- 2021-11-16 US US17/527,514 patent/US11827656B2/en active Active
-
2023
- 2023-10-17 US US18/380,962 patent/US20240199655A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111491938B (zh) | 2024-05-24 |
| CO2020007150A2 (es) | 2020-06-19 |
| US20220073538A1 (en) | 2022-03-10 |
| ZA202002531B (en) | 2023-10-25 |
| MX2020005046A (es) | 2020-08-20 |
| NZ764393A (en) | 2023-11-24 |
| PH12020550580A1 (en) | 2021-04-26 |
| US11225493B2 (en) | 2022-01-18 |
| EP3710458A1 (en) | 2020-09-23 |
| WO2019099582A1 (en) | 2019-05-23 |
| TWI837104B (zh) | 2024-04-01 |
| US11827656B2 (en) | 2023-11-28 |
| CA3080949A1 (en) | 2019-05-23 |
| MA50906A (fr) | 2020-09-23 |
| JP7277457B2 (ja) | 2023-05-19 |
| US20200277312A1 (en) | 2020-09-03 |
| BR112020009516A2 (pt) | 2020-11-03 |
| MX2022012825A (es) | 2022-11-07 |
| KR20200085868A (ko) | 2020-07-15 |
| IL274523B2 (en) | 2024-02-01 |
| CN111491938A (zh) | 2020-08-04 |
| IL274523A (en) | 2020-06-30 |
| EA202090900A1 (ru) | 2020-10-02 |
| US20240199655A1 (en) | 2024-06-20 |
| AU2018367515B2 (en) | 2023-04-27 |
| CA3080949C (en) | 2024-04-16 |
| AU2018367515A1 (en) | 2020-05-14 |
| TW201930264A (zh) | 2019-08-01 |
| JP2021503471A (ja) | 2021-02-12 |
| SG11202003867SA (en) | 2020-05-28 |
| IL274523B1 (en) | 2023-10-01 |
| KR102625984B1 (ko) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001244A1 (es) | Inhibidores de inmunoproteasoma. | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| BR112018070677A2 (pt) | inibidores de mcl-1 macrocíclicos para o tratamento de câncer | |
| CL2019002204A1 (es) | Compuestos inhibidores del vih. | |
| CL2019003086A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| CO2017011172A2 (es) | Compuestos de 1-ciano-pirrolidina como inhibidores de usp30 | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| ECSP22019360A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| CU20160111A7 (es) | Compuestos de heterociclilo bicíclico como inhibidores de irak4 | |
| UY35243A (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| MX347988B (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| AR091857A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| MX2018001992A (es) | Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. | |
| PE20180412A1 (es) | Compuestos inhibidores de la senalizacion de la via de notch | |
| AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| MX2019006843A (es) | Inhibidor de cdk4/6. | |
| UY37569A (es) | Inhibidores del inmunoproteasoma | |
| WO2015195950A8 (en) | Lmp7 inhibitors |